1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Procedure and device characteristics
Characteristics IPH/Subtotal^{^a} OR P Value
Preprocedural antiplatelet use 
    Yes 2.5% (17/681) 0.93 (0.27–3.23) .91
    No 2.7% (3/112) Ref 
Preprocedural platelet aggregation studies 
    Yes 2.5% (14/564) 0.95 (0.36–2.49) .91
    No 2.6% (6/229) Ref 
Heparin administration 
    Yes 2.6% (18/704) 1.14 (0.26–5.00) .86
    No 2.2% (2/89) Ref 
Reversal of heparin 
    Yes 5.6% (1/18) 2.33 (0.29–18.49) .43
    No 2.5% (17/689) Ref 
No. of PEDs used 
    1 1.7% (9/533) Ref 
    2 3.3% (6/183) 1.97 (0.69–5.62) .96
    3+ 6.6% (5/76) 4.10 (1.34–12.58) .04
How multiple PEDs were used 
    Overlapping 1.4% (2/140) Ref 
    Multiple layers 7.5% (3/40) 5.59 (0.90–34.72) .96
    Additional length 7.9% (6/76) 5.91 (1.16–30.06) .96
    Multiple layers and overlapping 0.0% (0/2) NA 
Sheaths used 
    Medical Arrow-Flex^{^b} 
        Yes 0.0% (0/35) NA 
        No 3.5% (19/546) 
    Medical Shuttle Select 
        Yes 3.2% (8/249) 0.97 (0.38–2.45) .95
        No 3.3% (11/332) Ref 
    Pinnacle Destination^{^c} 
        Yes 5.9% (2/34) 1.95 (0.43–8.80) .39
        No 3.1% (17/547) Ref 
Microcatheter used 
    Marksman^{^d} 
        Yes 3.2% (18/557) 0.77 (0.10–6.00) .80
        No 4.2% (1/24) Ref 
↵a The number of IPHs does not add up to 20 in all subanalyses because these data were missing in some patients.
↵b Teleflex, Limerick, Pennsylvania.
↵c Terumo, Tokyo, Japan.
↵d Covidien, Irvine, California.